Dorui Pharmaceutical announced that the company plans to transfer 100% of its shares in the subsidiary Hubei Dorui Pharmaceutical Co., Ltd. to Xizang Jiakang Times Technology Development Co., Ltd., which holds more than 5% of the shares, at a transaction price of 77.264,500 yuan. This transaction constitutes a related transaction and does not constitute a major asset restructuring. After completion, the company no longer holds shares in Hubei Duorui, and it is no longer included in the scope of the consolidated statement. As of May 31, 2026, Hubei Dorui had net assets of 58.9063 million yuan and a net loss of 7.1381 million yuan from January to May 2026. The company's receivables of RMB 37.8097 million from Hubei Dorui will be assisted by Tibet Jiakang before the share change is registered. The transaction still needs to be submitted to the company's shareholders' meeting for review, and the proceeds will be used to supplement the company's working capital.

Dorui Pharmaceutical announced that the company plans to transfer 100% of its shares in the subsidiary Hubei Dorui Pharmaceutical Co., Ltd. to Xizang Jiakang Times Technology Development Co., Ltd., which holds more than 5% of the shares, at a transaction price of 77.264,500 yuan. This transaction constitutes a related transaction and does not constitute a major asset restructuring. After completion, the company no longer holds shares in Hubei Duorui, and it is no longer included in the scope of the consolidated statement. As of May 31, 2026, Hubei Dorui had net assets of 58.9063 million yuan and a net loss of 7.1381 million yuan from January to May 2026. The company's receivables from Hubei Dorui amounting to RMB 37.8097 million will be repaid with the assistance of Tibet Jiakang before the share change is registered. The transaction still needs to be submitted to the company's shareholders' meeting for review, and the proceeds will be used to supplement the company's working capital.